BCRX Biocryst Pharmaceuticals Inc.

$BCRX yall ever day dream about waking up one day to an actual buyout? No more bullshit manipulation, no more being held at half what we’re worth, no more massive sell offs for years on end on mostly good news. Just easy peasy profit and no stress. God I’m praying here lol

$BCRX Interesting uptick in volume. Will be interesting to see if there is a gradual continuation of this the remainder of Oct. We have Q3 ER coming up on or around Nov 2 and there are potentially two paths to an early 17725 November announcement: 1. Primary dataset only: Last patient completes Week 12 in October → database cleaned/analyzed → topline POC announced in November, while some patients remain in follow-up. 2. Nearly complete/full dataset: Last patient actually reaches Week 12 early enough in October that the eight-week follow-up concludes in late November → BioCryst analyzes efficacy plus follow-up and announces around late November/early December. The first scenario is especially plausible because this is an open-label study of only up to 12 patients, not a large blinded Phase 3 requiring an elaborate database lock. If anyone was considering taking up a position in the stock this week and next is going to be the best time to do it.

$BCRX how can leadership possibly defend a sub-$8/share position and still say one of their primary goals is to create shareholder value. I fucking hate this stock. There is NO reason we should be in the $7's when generating the revenues that we do. I'm just so over this company. I feel like I'm being held prisoner waiting for any sort of respectable return on my investment.

$BCRX IMO: The "gap" that financial and biotech analysts previously perceived between Orladeyo and Pharvaris’s drug (deucrictibant, in an extended-release [XR] formulation for prophylaxis) is narrowing significantly for two key reasons: Analysts had initially penalized Orladeyo (capsules) by citing abdominal pain and diarrhea—which affected over 20% of patients in pivotal trials—as a commercial drawback compared to the tolerability profile of deucrictibant. When compared to the granule (pellet) formulation, however, acute gastric irritation caused by direct contact is almost entirely eliminated, bringing discontinuation rates due to gastrointestinal issues down to zero and resulting in an exceptionally clean digestive tolerability profile. .....

$BCRX Isn’t AI just great? Right now anyway for things like generating an amusing pic to post. Wish I would’ve invested it all in that shit 6 years ago. I would have my bullets, beans and cabin in the middle of nowhere by now. Too bad we’re so close to the threshold of unmitigated super intelligence and the destruction of humanity. Skynet will undoubtedly become self aware the day before our positive data drops.

$BCRX FWIW we are already up to 2.7 million block traded shares today. That is unusual before end of day. 🤔

$BCRX This is great news. I have said this before multiple times since September 2020... this will be bought out. Everything coming together for a Nov, Dec or Jan Buy Out. News today is very big. Revenue over 600 MIL and counting. Perfect bolt on for a Rare Disease Pharma

$BCRX SI has not been this low as long as I can remember, and I've been in the 📩Stock for a long time The big drop a few weeks ago let some of the shorts off easily Keep adding Buyout sooner or later 🙏

$BCRX At the TD Cowen conference earlier this year Charlie stated that there are approximately 500 diagnosed children versus an estimated 1,100–1,200 who may have HAE. He also said that only 40% of diagnosed children reportedly receive prophylaxis. That leaves approximately 300 diagnosed children who are not receiving preventive treatment. If you use 1,150 children (to be a bit more conservative) with Charlie’s current diagnosis and treatment figures produces approximately 200 children on prophy. If diagnosis increases to 70% and prophy use reaches 60%, the treated population grows to roughly 483 children. That is more than twice the current estimated prophylaxis market without any increase in underlying HAE prevalence. 483 pediatric patients receiving Orladeyo for a full year could generate approximately $200–$250 M in annual net revenue, with a midpoint of roughly $225 M. 2027 = full year with mfg, formulary, prescribers in place. Power to the pellets

$BCRX So morning of November 4th for ER. Thank heavens we don't have any large market moving events happening on the evening of the November 3rd.

$BCRX A helping of "Buyout Brownies" will now be served to visitors to the board speculating on a buyout. Today's delicious serving comes sprinkled with Orladeyo pellets. 🤤

$BCRX for the first time since January 2021 I'm thinking to sell this thing the next time it hits 10. Like, I'm tired. Almost never in red but man, I would have never thought this would have been so boring to hold.

$BCRX If you factor in the increase in the amount of shares outstanding, BCRX currently has about the same MC it did in January 2023. During that time the company has become cash flow positive, become profitable, increased sales every year, acquired a new late stage asset, approved pediatric Orladeyo, sold the unprofitable EUR business to pay off debt, and had expense reductions. Among other things. ALL OF THAT, and not worth anything more than it was almost 4 years ago. Well done management.

$BCRX congrats to the longs that have endured the wait this run here should put you back at 12.40’s next jump you guys will see is back to 9.10 range and than get the break and run.

$BCRX Only as memo: the official data (not to confuse with real data): Orladeyo pill = 44% (24wks) Orladeyo pellets = 74% (48wks) In real world they are the same outcomes but now that bad 44% can be forgotten ....

$BCRX Granules / Pellets (Pediatric - APeX-P): In the clinical trial involving pellets, the overall incidence of gastrointestinal (GI) disturbances was markedly lower. The most frequent adverse reactions were respiratory in nature (nasopharyngitis in 34.5% of cases, upper respiratory tract infections in 27.6%). Reported GI events were limited to isolated episodes of vomiting (17.2%) or nausea/mild discomfort, with a clear reduction in acute abdominal pain and diarrhea compared to the rates observed with capsules. No patient in the APeX-P trial discontinued or interrupted treatment due to gastrointestinal adverse events. Granule Coating (Micro-pellet Coating): Traditional capsules break down rapidly in the stomach, releasing a concentrated mass of the active ingredient directly onto the gastric mucosa. .........

$BCRX tired of waiting. No insider buys, I want to see some stock buy backs before they buy more rare disease shit

$BCRX we now need a 40% run to be in the $10's. How have I been here a decade and didn't just buy puts every time this hits double digits. I'd be retired now

FDA NEWS | October 21, 2026 3 biotech stocks with fresh catalysts: $BCRX — FDA approves a new oral pellet formulation of ORLADEYO for hereditary angioedema. $IRD — FDA clears IND for OPGx-RDH12, allowing clinical development of its gene therapy for inherited childhood blindness. $ROIV — Positive Phase 3 results in two uveitis trials, both meeting their primary endpoints. Watching these names for momentum heading into October 22.

$BCRX Remeber the biggest kick to the nuts is the dilution that continues to take place. We would be a $13 stock today based on today’s market cap if we still had the 167 million shares outstanding that we did back in the early 2020s. They owe it to shareholders to start buying shares back!